scispace - formally typeset
X

Xiao-Ting Li

Researcher at Peking University

Publications -  100
Citations -  1368

Xiao-Ting Li is an academic researcher from Peking University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 13, co-authored 76 publications receiving 818 citations.

Papers
More filters
Journal ArticleDOI

Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

TL;DR: Using pre- and posttreatment MRI data, a radiomics model with excellent performance for individualized, noninvasive prediction of pCR is developed and may be used to identify LARC patients who can omit surgery after chemoradiotherapy.
Journal ArticleDOI

MRI of Extramural Venous Invasion in Locally Advanced Rectal Cancer: Relationship to Tumor Recurrence and Overall Survival

TL;DR: The presence of EMVI was associated with greater risk of local and distant tumor recurrence and overall death in patients with locally advanced rectal cancer treated with neoadjuvant chemotherapy-radiation therapy followed by surgery.
Journal ArticleDOI

YAP1 enhances cell proliferation, migration, and invasion of gastric cancer in vitro and in vivo

TL;DR: YAP1 is not a direct factor affecting tumor formation, but could accelerate tumor growth and metastasis, and it is suggested that YAP1 could possibly be a potential treatment target for GC.
Journal ArticleDOI

Evaluation of dose reduction and image quality in chest CT using adaptive statistical iterative reconstruction with the same group of patients

TL;DR: This study compared the image quality and radiation dose of chest CT images reconstructed with a blend of adaptive statistical iterative reconstruction (ASIR) and filtered back-projection (FBP) with images generated using conventional FBP.
Journal ArticleDOI

Prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer using a deep learning (DL) method.

TL;DR: The aim of the study was to develop a deep learning algorithm to evaluate the pathological complete response (pCR) to neoadjuvant chemotherapy in breast cancer.